Announcements Trials
Browse Landscape

Phase

Phase 1/2 4Phase 2 2Phase 1 2

Status

Recruiting 3Active not recruiting 3Terminated 2

Sponsor Class

INDUSTRY 8

Study Type

Interventional 8

Sponsor

Cancer Type

Other solid neoplasm 8

Conditions

Carcinoma, Non-Small-Cell Lung 461Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Breast Neoplasms 162Triple Negative Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 146Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 100Carcinoma, Transitional Cell 91Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Carcinoma, Hepatocellular 74Endometrial Neoplasms 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Carcinoma, Squamous Cell 39Small Cell Lung Carcinoma 38Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

Paclitaxel 15atezolizumab 11Gemcitabine 11Carboplatin 9pembrolizumab 8Docetaxel 8Bevacizumab 8Irinotecan 7Injections 6Cetuximab 6Capecitabine 6Sunitinib 5Leucovorin 5Fluorouracil 5Cyclophosphamide 5tocilizumab 4pazopanib 4olaparib 4navitoclax 4liposomal doxorubicin 4Topotecan 4Oxaliplatin 4Nivolumab 4Erlotinib Hydrochloride 4temsirolimus 3spartalizumab 3lenvatinib 3fludarabine 3cobimetinib 3Cisplatin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

8 trials
RecentStart dateEnrollment
Solid Tumors × pembrolizumab × Clear all
NCT07415031 2026-05-15

A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies

Mirati Therapeutics Inc.

Phase 2 Recruiting
170 enrolled
Other solid neoplasm

Solid Tumors

NCT04123366 2026-04-22

MK-7339-007

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
300 enrolled
Other solid neoplasm

Solid Tumors

NCT03917381 2026-04-06

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

Genmab

Phase 1/2 Active not recruiting
429 enrolled
Other solid neoplasm

Solid Tumors

NCT05101070 2026-03-18

aCCeleR8-001

Shionogi Inc.

Phase 1/2 Recruiting
282 enrolled
Other solid neoplasm

Solid Tumors

NCT03313778 2026-03-04

KEYNOTE-603

ModernaTX, Inc.

Phase 1 Active not recruiting
161 enrolled
Other solid neoplasm

Solid Tumors

NCT07158918 2025-09-08

ABL103 in Combination With Pembrolizumab, With or Without Taxane in Advanced or Metastatic Solid Tumors

ABL Bio, Inc.

Phase 1/2 Recruiting
65 enrolled
Other solid neoplasm

Solid Tumors

NCT05996445 2024-08-23

A Study of XmAb®662 as Monotherapy or in Combination With Pembrolizumab in Advanced Solid Tumors

Xencor, Inc.

Phase 1 Terminated
7 enrolled
Other solid neoplasm

Solid Tumors

NCT02587962 2021-01-14

Dose-escalation Study of Birinapant and Pembrolizumab in Solid Tumors

Medivir

Phase 1/2 Terminated
34 enrolled 27 charts
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡